Fang Chen^*, Dongqiang Yang^†, Yuhua Ru^‡, Shan Cao^*, Aishe Gao^*

Oncology Research, Vol.27, No.6, pp. 691-701, 2019, DOI:10.3727/096504018X15426763753594

Abstract Escalating evidence suggests that microRNA-101 (miR-101) is implicated in the development and progression of various cancers, including papillary thyroid carcinoma (PTC). However, the biological function and molecular mechanisms of miR-101 in PTC are still unclear. In this study, we demonstrated that miR-101 expression was significantly decreased in PTC tissues and cell lines. Clinically, a low level of miR-101 was positively associated with advanced histological stages and lymph node and distant metastases. The expression of CXCL12 was negatively correlated with miR-101 level in PTC. CXCL12 was validated as a direct target of miR-101 in PTC cells. Functional experiments proved that miR-101… More >

Hyeong Won Yu¹, Muhammad Afzal², Maqbool Hussain², Hyungju Kwon³, Young Joo Park⁴, June Young Choi^1,*, Kyu Eun Lee⁵

CMC-Computers, Materials & Continua, Vol.67, No.1, pp. 1241-1251, 2021, DOI:10.32604/cmc.2021.014910

Abstract Advances in technology are enabling gene mutations in papillary thyroid carcinoma (PTC) to be analyzed and clinical outcomes, such as recurrence, to be predicted. To date, the most common genetic mutation in PTC is in BRAF kinase (BRAF). However, whether mutations in other genes coincide with those in BRAF remains to be clarified. The aim of this study was to find mutations in other genes that co-exist with mutated BRAF, and to analyze their frequency and clinical relevance in PTC. Clinical and genetic data were collected from 213 PTC patients with a total of 36,572 mutation sites in 735 genes.… More >